Tag Archives: KPTI

Analysts’ Perspective: Tech Data Corp. (TECD), Karyopharm Therapeutics (KPTI), Oasis Petroleum (OAS)

Tech Data Corp. (NASDAQ:TECD) shares were upgraded by analysts at BofA/Merrill from Underperform to Neutral rating.

Tech Data Corporation engages in the wholesale distribution of technology products. It distributes and markets broadline products, such as notebooks, tablets, desktop systems, printers, supplies, and components; and data center products, including servers, proprietary servers, networking, and storage products.


Brokerage Firm Jefferies upgraded Karyopharm Therapeutics, Inc. (NASDAQ:KPTI) shares from Hold to Buy rating.

Karyopharm Therapeutics Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of drugs directed against nuclear transport and related targets for the treatment of cancer and other diseases. Its lead drug candidate is Selinexor, which is in Phase IIb clinical trial for patients with heavily pretreated multiple myeloma; Phase Ib/II clinical study in combination with backbone treatments for relapsed/refractory multiple myeloma; Phase II/III clinical trial for patients with relapsed and/or refractory multiple myeloma; Phase II clinical study to treat acute myeloid leukemia; Phase IIb clinical trial for patients with diffuse large B-cell lymphoma; and Phase II/III clinical trial to treat liposarcoma.


Investment Analysts at Seaport Global Securities upgraded Oasis Petroleum Inc. (NYSE:OAS) shares from Neutral to Accumulate rating.

Oasis Petroleum Inc., an independent exploration and production company, focuses on the acquisition and development of unconventional oil and natural gas resources in the North Dakota and Montana regions of the Williston Basin. Its principal projects are located in West Williston and East Nesson.


Disclaimer: The disclaimer is to be read and fully understood before using our site, or joining our email list. CRWE.Info is not a registered investment adviser. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Investors should always conduct their own due diligence with any potential investment, with independent research and other professional advice. Read full disclaimer at http://www.crwe.info/disclaimer/